Authors: Schwartz, G Johnson, TR Goetz, A Burris, H Smetzer, L Lampkin, T Sailstad, J Hohneker, JA Von Hoff, DD Rowinsky, EK

Citation: G. Schwartz et al., A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitorof thymidylate synthase, in patients with advanced solid malignancies, CLIN CANC R, 7(7), 2001, pp. 1901-1911

Authors: Smalley, RV Guaspari, A Haase-Statz, S Anderson, SA Cederberg, D Hohneker, JA

Citation: Rv. Smalley et al., Allopurinol: Intravenous use for prevention and treatment of hyperuricemia, J CL ONCOL, 18(8), 2000, pp. 1758-1763

Authors: Baker, SD Diasio, RB O'Reilly, S Lucas, VS Khor, SP Sartorius, SE Donehower, RC Grochow, LB Spector, T Hohneker, JA Rowinsky, EK

Citation: Sd. Baker et al., Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J CL ONCOL, 18(4), 2000, pp. 915-926

Authors: Havlin, KA Ramirez, MJ Legler, CM Harris, LN Matulonis, UA Hohneker, JA Hayes, DF Winer, EP

Citation: Ka. Havlin et al., Inability to escalate vinorelbine dose intensity using a daily x3 schedulewith and without filgrastim in patients with metastatic breast cancer, CANC CHEMOT, 43(1), 1999, pp. 68-72